Despite the current lack of drugs and pharmacological approaches with high specificity to effectively perturb nuclear condensates in tRCC, our chemogenetic studies employing split nanobody-MBP as a prototype point to the exciting possibility of selective dissolution of oncogenic condensates for cancer intervention. Here, MBP is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.